ATE249238T1 - Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten - Google Patents

Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten

Info

Publication number
ATE249238T1
ATE249238T1 AT01957136T AT01957136T ATE249238T1 AT E249238 T1 ATE249238 T1 AT E249238T1 AT 01957136 T AT01957136 T AT 01957136T AT 01957136 T AT01957136 T AT 01957136T AT E249238 T1 ATE249238 T1 AT E249238T1
Authority
AT
Austria
Prior art keywords
thrombin
therapy
relates
cardiovascular diseases
derived peptides
Prior art date
Application number
AT01957136T
Other languages
German (de)
English (en)
Inventor
Darrell H Carney
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE249238T1 publication Critical patent/ATE249238T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
AT01957136T 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten ATE249238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21758300P 2000-07-12 2000-07-12
PCT/US2001/021944 WO2002004008A2 (en) 2000-07-12 2001-07-12 Methods of therapy with thrombin derived peptides

Publications (1)

Publication Number Publication Date
ATE249238T1 true ATE249238T1 (de) 2003-09-15

Family

ID=22811661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957136T ATE249238T1 (de) 2000-07-12 2001-07-12 Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten

Country Status (10)

Country Link
US (5) US6867190B2 (enExample)
EP (1) EP1253937B1 (enExample)
JP (2) JP3618736B2 (enExample)
CN (1) CN100500211C (enExample)
AT (1) ATE249238T1 (enExample)
AU (2) AU2001278907B2 (enExample)
CA (1) CA2415778A1 (enExample)
DE (2) DE60100740T4 (enExample)
TW (1) TWI257307B (enExample)
WO (1) WO2002004008A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2002241917B2 (en) * 2000-07-12 2006-06-15 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US7803149B2 (en) * 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2511223A1 (en) * 2002-01-16 2003-07-31 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
EP1539800B1 (en) * 2002-07-02 2007-05-23 Orthologic Corp. Thrombin peptide derivative dimers
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2004211592B2 (en) 2003-02-12 2008-04-10 Monsanto Technology Llc Cotton event MON 88913 and compositions and methods for detection thereof
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
DE602004005564T2 (de) * 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
CA2576971A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
JP2006321740A (ja) * 2005-05-18 2006-11-30 Kanazawa Univ 虚血後血管新生促進剤
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
CA2663547C (en) * 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
EP2155236A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for cardiac revascularization and cardiac repair
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
US8586398B2 (en) * 2008-01-18 2013-11-19 Miasole Sodium-incorporation in solar cell substrates and contacts
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
US20130101574A1 (en) * 2010-06-11 2013-04-25 Darrell H. Carney Methods of using thrombin peptide derivatives
GB201314312D0 (en) * 2013-08-09 2013-09-25 Regentec Ltd Composition and delivery system
US20160039876A1 (en) 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
WO2020210087A1 (en) * 2019-04-12 2020-10-15 Affirmed Pharma, Llc Rusalatide acetate compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0697883A1 (en) 1993-04-29 1996-02-28 Washington University Use of platelet-derived growth factor to improve collateral circulation
ATE273322T1 (de) * 1995-10-24 2004-08-15 Chemo Sero Therapeut Res Inst Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
JP2002512200A (ja) 1998-04-17 2002-04-23 アンジオジェニックス， インコーポレイテッド 治療的な脈管形成因子およびその使用方法
CA2340593C (en) 1998-10-26 2012-05-08 Kari Alitalo Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair

Also Published As

Publication number Publication date
DE60100740D1 (de) 2003-10-16
JP3618736B2 (ja) 2005-02-09
TWI257307B (en) 2006-07-01
CN1455678A (zh) 2003-11-12
JP2004502739A (ja) 2004-01-29
CN100500211C (zh) 2009-06-17
EP1253937A2 (en) 2002-11-06
AU7890701A (en) 2002-01-21
HK1060302A1 (zh) 2004-08-06
WO2002004008A2 (en) 2002-01-17
US7034001B2 (en) 2006-04-25
AU2001278907B2 (en) 2004-10-21
US6867190B2 (en) 2005-03-15
US20060134167A1 (en) 2006-06-22
WO2002004008A3 (en) 2002-08-22
US6861407B2 (en) 2005-03-01
US20050153884A1 (en) 2005-07-14
US20080131474A1 (en) 2008-06-05
DE60100740T4 (de) 2005-01-27
DE60100740T2 (de) 2004-07-01
US7214661B2 (en) 2007-05-08
EP1253937B1 (en) 2003-09-10
US20020061852A1 (en) 2002-05-23
US20020187933A1 (en) 2002-12-12
JP2005036007A (ja) 2005-02-10
US7732411B2 (en) 2010-06-08
CA2415778A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
ATE249238T1 (de) Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten
JP2004502739A5 (enExample)
WO2003032815A3 (en) Medical device for delivering patches
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
DK1009425T3 (da) Anvendelse af latens-associeret-peptid til fremstilling af et medikament til forøgelse af sårheling
ATE399002T1 (de) Pharmazeutische zubereitungen für die behandlung von läsionen der haut und schleimhäute und diese verwendende verfahren und kits
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ES2195025T3 (es) Proteinas de fusion de un dominio de factor tisular-dominio de kunitz como inhibidores del factor viia.
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
DE60239705D1 (de) Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
PT1039884E (pt) Metodo para a prevencao e tratamento do miocardio aturdido
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
JP2003528919A5 (enExample)
SE9902597D0 (sv) New use
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
DE69904465D1 (de) Therapie von depressionen
ITMI20001257A0 (it) Composizione farmaceutica a base di prolina, glicina e lisina utile nella terapia per la cicatrizzazione delle ferite e delle lesioni tendin
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253937

Country of ref document: EP